Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice

被引：19
|
作者：
Litten, Raye Z. [1 ]
Falk, Daniel E. [1 ]
Ryan, Megan L. [1 ]
Fertig, Joanne [1 ]
Leggio, Lorenzo [2 ,3 ,4 ]
机构：
[1] NIAAA, Bethesda, MD USA
[2] NIAAA, Sect Clin Psychoneuroendocrinol & Neuropsychophar, NIH, Bethesda, MD USA
[3] NIDA, Medicat Dev Program, NIH, Baltimore, MD USA
[4] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA
来源：
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH | 2020年 / 44卷 / 01期
关键词：
Medications; Alcohol Use Disorder; Personalized Medicine; Targets; Screening Models; Medication Use; Health Services; Dissemination; PLACEBO-CONTROLLED TRIAL; ADDICTIONS NEUROCLINICAL ASSESSMENT; CELL-BASED MODELS; DOUBLE-BLIND; NALTREXONE RESPONSE; PRIMARY-CARE; DEPENDENT INDIVIDUALS; EXPRESSION SIGNATURES; RECEPTOR ANTAGONIST; PRECISION MEDICINE;
D O I：
10.1111/acer.14233
中图分类号：
R194 [卫生标准、卫生检查、医药管理];
学科分类号：
摘要：
引用
收藏
页码：23 / 35
页数：13
相关论文
共 50 条
  • [1] Medications for Alcohol Use Disorder
    Poorman, Elisabeth
    McQuade, Brianna M.
    Messmer, Sarah
    AMERICAN FAMILY PHYSICIAN, 2024, 109 (01) : 71 - 78
  • [2] Medications for Alcohol Use Disorder
    Winslow, Bradford T.
    Onysko, Mary
    Hebert, Melanie
    AMERICAN FAMILY PHYSICIAN, 2016, 93 (06) : 457 - 465
  • [3] Overcoming the "Valley of Death" in Medications Development for Alcohol Use Disorder
    Ray, Lara A.
    Bujarski, Spencer
    Roche, Daniel James Olan
    Magill, Molly
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2018, 42 (09) : 1612 - 1622
  • [4] GABAERGIC MEDICATIONS IN THE TREATMENT OF ALCOHOL USE DISORDER: THEIR EVOLUTION IN EUROPEAN PRACTICE
    Addolorato, G.
    ALCOHOL AND ALCOHOLISM, 2014, 49
  • [5] A Practice-Quit Model for Screening Medications for Alcohol Use Disorder
    Ray, Lara
    Nieto, Steven
    Grodin, Erica
    Basker-Ville, Wave-Ananda
    Ho, Diana
    Russell, Riley
    Gillis, Artha
    Miotto, Karen
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 : 416 - 416
  • [6] A practice-quit model for screening medications for alcohol use disorder
    Baskerville, W.
    Nieto, S.
    Grodin, E. N.
    Ho, D.
    Russell, R.
    Gillis, A.
    Miotto, K.
    Ray, L. A.
    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 47 : 239 - 239
  • [7] The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
    De Beaurepaire, Renaud
    Sinclair, Julia M. A.
    Heydtmann, Mathis
    Addolorato, Giovanni
    Aubin, Henri-Jean
    Beraha, Esther M.
    Caputo, Fabio
    Chick, Jonathan D.
    de la Selle, Patrick
    Franchitto, Nicolas
    Garbutt, James C.
    Haber, Paul S.
    Jaury, Philippe
    Lingford-Hughes, Anne R.
    Morley, Kirsten C.
    Muller, Christian A.
    Owens, Lynn
    Pastor, Adam
    Paterson, Louise M.
    Pelissier, Fanny
    Rolland, Benjamin
    Stafford, Amanda
    Thompson, Andrew
    van den Brink, Wim
    Leggio, Lorenzo
    Agabio, Roberta
    FRONTIERS IN PSYCHIATRY, 2019, 9
  • [8] Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development
    Litten, Raye Z.
    Falk, Daniel E.
    Ryan, Megan L.
    Fertig, Joanne B.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2016, 40 (07) : 1368 - 1379
  • [9] Topiramate Treatment of Alcohol Use Disorder in Clinical Practice
    Jefee-Bahloul, Hussam
    Jorandby, Lantie
    Arias, Albert J.
    JOURNAL OF ADDICTION MEDICINE, 2019, 13 (01) : 23 - 27
  • [10] A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial
    Ray, Lara A.
    Baskerville, Wave-Ananda
    Nieto, Steven J.
    Grodin, Erica
    Enders, Craig
    Kady, Annabel
    Meredith, Lindsay
    Gillis, Artha
    Leventhal, Adam
    Ho, Diana
    Miotto, Karen
    PSYCHOPHARMACOLOGY, 2024, 241 (03) : 543 - 553
12345